You are here: University of Sydney / Engineering & IT / About us / Our people / Dr Colin Dunstan 

Dr Colin Dunstan

BSc Sydney, MSc UNSW, PhD Sydney
Principal Research Fellow
Associate Professor
School of Aerospace, Mechanical and Mechatronic Engineering

J07 - Mechanical Engineering Building
The University of Sydney

Telephone +61 2 9351 7127
Fax +61 2 9351 7060

Website ANZAC Research Institute

Biomechanics, Biomaterials and Tissue Engineering

Aerospace, Mechanical and Mechatronic Engineering

Biographical details

Associate Professor Colin Dunstan is a respected authority on bone metabolism with over 25 years of experience in both clinical and basic research. He was part of the team that identified osteoprotegerin, RANK ligand and RANK as central regulators of bone resorption. He has extensive experience in both academic and industry (Amgen) settings. He currently serves on the editorial boards of Endocrinology and the Journal of Bone and Mineral Research. Current research interests are in the local regulation of bone remodelling and in interactions between bone cell activity and cancer cells.
Back to Top

Research interests

Associate Professor Colin Dunstan researches the process of cancer metastasis to bone. Research activities cover establishment of animal models of breast cancer metastasis to bone, evaluating targeting to bone, lytic processes, and tumor growth in the bone environment, and the interactions of bones cells and cancer cells that promote metastasis. He focuses on the interactions between cancer cells and the regulation of bone resorption through the cytokines RANK ligand and osteoprotegerin.

A related area of interest is the evaluation of transgenic and knockout mice to define skeletal phenotypes. Associate Professor Dunstan has extensively studied mice genetically modified to alter the expression of osteocalcin, RANK ligand, its associated receptor RANK, and its decoy receptor osteoprotegerin.

Associate Professor Dunstan has direct experience in the clinical application and commercial translation of discoveries in bone biology. He is experienced in regulatory requirements for preclinical and early clinical studies of new therapeutics, having taken osteoprotegerin from initial in vivo studies through to successful IND filing and completion of a phase 1 trial. He has broad experience in clinical research of metabolic bone diseases as assessed by bone histomorphometry.
Back to Top

Teaching and supervision

AMME4990 - Biomedical Product Development
AMME5022 - Capstone Project B Extended
AMME5901 - Anatomy and Physiology for Engineers
AMME5990 - Biomedical Engineering Technology 1
ENGG1960 - Introduction to Biomedical Engineering
MECH2901 - Anatomy and Physiology for Engineers
MECH3661 - Engineering Management
Back to Top

Themes

Biomedical engineering and technology; Cancer; Healthy Ageing

Back to Top

Selected grants

2013

  • Novel Cytoplasmic Functions of the Vitamin D Receptor in Bone Metastases; Seibel M, Zhou H, Zheng Y, Dunstan C; Cancer Council New South Wales/Research Project Grants.
  • Microstructural Design Strategies for Repairing Traumatic Skeletal Injuries; Zreiqat H, Dunstan C; Rebecca L Cooper Medical Research Foundation/Equipment Grant.
  • ATVRE - Assistive Technologies for Virtual Rehabilitation Engineering; Feng D, Dehghani F, Dunstan C, Jin C, Kim J, Li Q, McEwan A, Ruys A, Brooker G, Buckley T, Cai W, Davis G, Fornusek C, Fulham M, Khadra M, Mohamed A, Murray G, Peck C, Vucetic B, Weiss A; DVC Research/Research Network Scheme (SyReNS).

2012

  • Pharmacological development of synthetic analogues of cytochrome P450-mediated omega-3 fatty acid epoxides as novel anti-metastatic agents; Murray M, Duke C, Cui P, Ching L, Dunstan C; National Health and Medical Research Council/Project Grants.

2011

  • The Instron testing material instrument (Model 5943); Dehghani F, Weiss A, Bilek M, Zreiqat H, Dunstan C, Chrzanowski W, Rohanizadeh R; National Health and Medical Research Council/Equipment Grants.

2010

  • Novel coatings for orthopaedic application; Zreiqat H, Sonnabend D, Dunstan C; Australian Orthopaedic Association Research Foundation Ltd/Research Support.
  • Harnessing the physiological effects of strontium and zinc to produce novel biomaterials for orthopaedic applications; Zreiqat H, Dunstan C; National Health and Medical Research Council/Project Grants.
  • The Role of the Osteoblast in Mediating Glucocorticoid-induced Metabolic Dysfunction; Seibel M, Zhou H, Gundberg C, Dunstan C; National Health and Medical Research Council/Project Grants.

2009

  • Novel coatings for orthopaedic implants; Grau G, Little D, Zreiqat H, Dunstan C; National Health and Medical Research Council/Project Grants.
  • Osteoblast Control of Mesenchymal Progenitor Cell Differentiation: The Role of Glucocorticoids and Wnt Signalling; Zhou H, Chen D, Seibel M, Chen D, Dunstan C; National Health and Medical Research Council/Project Grants.

2008

  • Novel Scaffolds for repairing bone defects; Zreiqat H, Little D, Dunstan C; Australian Orthopaedic Association Research Foundation Ltd/Research Support.
  • FSH and Female Ageing; Allan C, Handelsman D, Dunstan C; NHMRC/Project Grant.

2007

  • Illumina BeadXpress Reader for VeraCode Technology; Dunstan C; NHMRC/Equipment Grant.
  • Leica CM3050 S cryostat; Seibel M, Blair J, Dunstan C, Handelsman D, Nicholson G, Kennerson M, Lowe H, Witting P, Allan C, Zhou H; University of Sydney/Major Equipment.

2006

  • Glucocorticoid effects on bone: the role of the osteoblast; Seibel M, Zhou H, Dunstan C, Krozowski Z; NHMRC/Project Grant.
  • KODAK Image Station 2000mm Multi-Modal Imager; Seibel M, Nicholson G, Witting P, Le Couteur D, Freedman S, Dunstan C, Blair J, Kennerson M, Myers S, Muller M; University of Sydney/Major Equipment.
  • Cell culture quarantine and storage facility plus assessories; Dunstan C, Witting P, Myers S, Handelsman D, Seibel M, Nicholson G, Zhou H, Kennerson M, Allan C, Freedman S, Le Couteur D, Muller M; NHMRC/Equipment Grant.

2005

  • Bone resorption in breast cancer metastasis; Blair J, Dunstan C, Seibel M, Zhou H; NHMRC/Project Grant.
  • Equipment Grant Glucocorticoids in inflammatory arthritis.; Dunstan C, Seibel M; Rebecca L Cooper/Medical Research Foundation.
  • Bio-Rad iCycler iQ5 Real-Time PCR & Mutation detection system; Seibel M, Le Couteur D, Freedman S, Nicholson G, Handelsman D, Kennerson M, Dunstan C, Allan C, Witting P, Kril J, Muller M; NHMRC/Equipment Grant.
Back to Top

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Pivonka, P., Buenzli, P., Dunstan, C. (2012). A Systems Approach to Understanding Bone Cell Interactions in Health and Disease. In Sivakumar Gowder (Eds.), Cell Interaction, (pp. 169-204). Rijeka, Croatia: InTech Publishers.
  • Dunstan, C. (2009). How can periodontal bone loss be stopped? In Seymour, Robert~Henderson, Brian~Donas, Nikolaos~Curtis, Michael~ (Eds.), Periodontal Medicine and Systems Biology, (pp. 427-237). Chichester, UK: Wiley-Blackwell Publishing.
  • Dunstan, C., Blair, J., Zhou, H., Seibel, M. (2007). Bone, Mineral, Connective Tissue Metabolism. In Taylor J; Triggle D (vol ed Michael Williams) (Eds.), Comprehensive Medicinal Chemistry II, (pp. 495-520). Oxford, United Kingdom: Elsevier.
  • Dunstan, C. (2005). The role of RANK, RANK ligand and osteoprotegerin in the lytic effects and growth of bone metastases. In Claude Jasmin, Lawrence R. Coia, Rodolfo Capanna, Gerard Saillant (Eds.), Textbook of bone metastases, (pp. 51-62). United States: John Wiley & Sons.

Journals

  • Zheng, Y., Zhou, H., Dunstan, C., Sutherland, R., Seibel, M. (2013). The role of the bone microenvironment in skeletal metastasis. Journal of Bone Oncology, 2(1), 47-57.
  • Smith, D., Gardiner, B., Dunstan, C. (2012). Bone Balance within a Cortical BMU: Local Controls of Bone Resorption and Formation. PLoS One, 7(7), 1-12.
  • Brennan, T., Henneicke, H., Gasparini, S., Blankenstein, K., Heinevetter, U., Cogger, V., Svistounov, D., Zhang, Y., Cooney, G., Buttgereit, F., Dunstan, C., Zhou, H., Seibel, M., et al (2012). Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism. Journal of Clinical Investigation, 122(11).
  • Roohani-Esfahani, S., Dunstan, C., Davies, B., Pearce, S., Williams, R., Zreiqat, H. (2012). Repairing a critical-sized bone defect with highly porous modified and unmodified baghdadite scaffolds. Acta Biomaterialia, 8(11), 4162-4172.
  • Pivonka, P., Dunstan, C. (2012). Role of mathematical modeling in bone fracture healing. BoneKEy Reports, Report 1 (2012), 221-1-221-10.
  • Lu, Z., Wang, G., Dunstan, C., Zreiqat, H. (2012). Short-Term Exposure to Tumor Necrosis Factor-Alpha Enables Human Osteoblasts to Direct Adipose Tissue-Derived Mesenchymal Stem Cells into Osteogenic Differentiation. Stem Cells and Development, 21(13), 2420-2429.
  • Kam, W., Meikle, S., Dunstan, C., Banati, R. (2012). The 18 kDa Translocator Protein (Peripheral Benzodiazepine Receptor) Expression in the Bone of Normal, Osteoprotegerin or Low Calcium Diet Treated Mice. PLoS One, 7(1), 1-10.
  • Stalgis-Bilinski, K., Boyages, J., Salisbury, E., Dunstan, C., Henderson, S., Talbot, P. (2011). Burning daylight: balancing vitamin D requirements with sensible sun exposure. Medical Journal of Australia, 194(7), 345-348.
  • Wang, Y., Pivonka, P., Buenzli, P., Smith, D., Dunstan, C. (2011). Computational Modeling of Interactions between Multiple Myeloma and the Bone Microenvironment. PLoS One, 6(11), e27494-1-e27494-21.
  • Henneicke, H., Herrmann, M., Kalak, R., Brennan, T., Bertollo, N., Day, R., Huscher, D., Buttgereit, F., Dunstan, C., Seibel, M., Zhou, H. (2011). Corticosterone selectively targets endo-cortical surfaces by an osteoblast-dependent mechanism. Bone, 49(4), 733-742.
  • Fiford, R., Tomitsch, M., Dunstan, C., Plumbe, R. (2011). Exploring how elements of studio teaching can improve student engagement. Synergy, 31(July), 46-52.
  • Ooi, L., Zheng, Y., Stalgis-Bilinski, K., Dunstan, C. (2011). The bone remodeling environment is a factor in breast cancer bone metastasis. Bone, 48(1), 66-70.
  • Goldhahn, J., Little, D., Mitchell, P., Fazzalari, N., Reid, I., Aspenberg, P., Marsh, D., Augat, P., Bavonratanavech, S., Bostrom, M., Dunstan, C., et al (2010). Evidence for anti-osteoporosis therapy in acute fracture situations-Recommendations of a multidisciplinary workshop of the International Society for Fracture Repair. Bone, 46(2), 267-271.
  • Allan, C., Kalak, R., Dunstan, C., McTavish, K., Zhou, H., Handelsman, D., Seibel, M. (2010). Follicle-stimulating hormone increases bone mass in female mice. Proceedings of the National Academy of Sciences (PNAS), Published online before print December 13, 2010, 1-6.
  • Liu, P., Kalak, R., Lue, Y., Jia, Y., Erkkila, K., Zhou, H., Seibel, M., Wang, C., Swerdloff, R., Dunstan, C. (2010). Genetic and Hormonal Control of Bone Volume, Architecture, and Remodeling in XXY Mice. Journal of Bone and Mineral Research, 25(10), 2148-2154.
  • Weber, A., Li, G., Kalak, R., Street, J., Buttgereit, F., Dunstan, C., Seibel, M., Zhou, H. (2010). Osteoblast-targeted disruption of glucocorticoid signalling does not delay intramembranous bone healing. Steroids, 75(3), 282-286.
  • Zreiqat, H., Ramaswamy, Y., Wu, C., Paschalidis, A., Lu, Z., James, B., Birke, O., McDonald, M., Little, D., Dunstan, C. (2010). The incorporation of strontium and zinc into a calcium-silicon ceramic for bone tissue engineering. Biomaterials, 31(12), 3175-3184.
  • Ooi, L., Zheng, Y., Zhou, H., Trivedi, T., Conigrave, A., Seibel, M., Dunstan, C. (2010). Vitamin D deficiency promotes growth of MCF-7 human breast cancer in a rodent model of osteosclerotic bone metastasis. Bone, 47(4), 795-803.
  • Ooi, L., Zhou, H., Kalak, R., Zheng, Y., Conigrave, A., Seibel, M., Dunstan, C. (2010). Vitamin D deficiency promotes human breast cancer growth in a murine model of bone metastasis. Cancer Research, 70(5), 1835-1844.
  • Zheng, Y., Zhou, H., Ooi, L., Snir, A., Dunstan, C., Seibel, M. (2010). Vitamin D deficiency promotes prostate cancer growth in bone. The Prostate, , 1-10.
  • Mak, W., Shao, X., Dunstan, C., Seibel, M., Zhou, H. (2009). Biphasic Glucocorticoid-Dependent Regulation of Wnt Expression and Its Inhibitors in Mature Osteoblastic Cells. Calcified Tissue International, 85(6), 538-545.
  • Wang, C., Karlis, G., Anderson, G., Dunstan, C., Carbone, A., Berger, G., Ploska, U., Zreiqat, H. (2009). Bone growth is enhanced by novel bioceramic coatings on Ti alloy implants. Journal of Biomedical Materials Research. Part A, 90A(2), 419-428.
  • Dunstan, C., Ooi, L. (2009). CXCL12/CXCR4 Axis in Tissue Targeting and Bone Destruction in Cancer and Multiple Myeloma. Journal of Bone and Mineral Research, 24(7), 1147-1149.
  • Kalak, R., Zhou, H., Street, J., Day, R., Modzelewski, J., Spies, C., Liu, P., Li, G., Dunstan, C., Seibel, M. (2009). Endogenous glucocorticoid signaling in osteoblasts is necessary to maintain normal bone structure in mice. Bone, 45(1), 61-67.
  • Zhou, H., Mak, W., Kalak, R., Street, J., Fong-Yee, C., Zheng, Y., Dunstan, C., Seibel, M. (2009). Glucocorticoid-dependent Wnt signaling by mature osteoblasts is a key regulator of cranial skeletal development in mice. Development (Cambridge), 136(3), 427-436.
  • Blair, J., Modzelewski, J., Perryman, L., Russell, P., Seibel, M., Dunstan, C. (2009). Prolonged Antiresorptive Treatment of Lytic Prostate Cancer Xenografts in Mouse Bone Results in Tumor Necrosis. Journal of Cancer Molecules, 4(6), 175-181.
  • Ramaswamy, Y., Wu, C., Dunstan, C., Hewson, B., Eindorf, T., Anderson, G., Zreiqat, H. (2009). Sphene ceramics for orthopedic coating applications: An in vitro and in vivo study. Acta Biomaterialia, 5(8), 3192-3204.
  • Herrmann, M., Henneicke, H., Street, J., Modzelewski, J., Kalak, R., Buttgereit, F., Dunstan, C., Zhou, H., Seibel, M. (2009). The challenge of continuous exogenous glucocorticoid administration in mice. Steroids, 74(2), 245-249.
  • Pivonka, P., Zimak, J., Smith, D., Gardiner, B., Dunstan, C., Sims, N., Martin, T., Mundy, G. (2009). Theoretical investigation of the role of the RANK-RANKL-OPG system in bone remodeling. Journal of Theoretical Biology, 262(2), 306-316.
  • Buttgereit, F., Zhou, H., Kalak, R., Gaber, T., Spies, C., Huscher, D., Straub, R., Modzelewski, J., Dunstan, C., Seibel, M. (2009). Transgenic Disruption of Glucocorticoid Signaling in Mature Osteoblasts and Osteocytes Attenuates K/BxN Mouse Serum-Induced Arthritis In Vivo. Arthritis Care and Research, 60(7), 1998-2007.
  • Zheng, Y., Zhou, H., Fong-Yee, C., Modzelewski, J., Seibel, M., Dunstan, C. (2008). Bone Resorption increases tumour growth in a mouse model of osteosclerotic breast cancer metastasis. Clinical and Experimental Metastasis, 25(5), 559-567.
  • Pivonka, P., Zimak, J., Smith, D., Gardiner, B., Dunstan, C., Sims, N., Martin, T., Mundy, G. (2008). Model structure and control of bone remodeling: A theoretical study. Bone, 43, 249-263.
  • Zhou, H., Mak, W., Zheng, Y., Dunstan, C., Seibel, M. (2008). Osteoblasts directly control lineage commitment of mesenchymal progenitor cells through WNT signaling. Journal of Biological Chemistry, 283(4), 1936-1945.
  • Zheng, Y., Zhou, H., Modzelewski, J., Kalak, R., Blair, J., Seibel, M., Dunstan, C. (2007). Accelerated bone resorption, due to dietary calcium deficiency, promotes breast cancer tumor growth in bone. Cancer Research, 67(19), 9542-9548.
  • Dunstan, C., Felsenberg, D., Seibel, M. (2007). Therapy insight: The risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nature Clinical Practice Oncology, 4(1), 42-45.
  • Zheng, Y., Brennan, K., Blair, J., Modzelewski, J., Seibel, M., Dunstan, C. (2006). Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone, 40(2), 471-478.
  • Blair, J., Zhou, H., Seibel, M., Dunstan, C. (2006). Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nature Clinical Practice Oncology, 3(1), 41-49.
  • Blair, J., Zheng, Y., Dunstan, C. (2006). RANK ligand. The International Journal of Biochemistry and Cell Biology, 39(6), 1077-1081.
  • Meier, C., Meinhardt, U., Greenfield, J., Modzelewski, J., Nguyen, T., Dunstan, C., Seibel, M. (2006). Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget's disease. Clinical Laboratory, 52(1-2), 1-10.
  • Seibel, M., Dunstan, C., Zhou, H., Allan, C., Handelsman, D. (2006). Sex steroids, not FSH, influence bone mass. Cell, 127(6), 1079-1079.
  • Geusens, P., Landewé, R., Garnero, P., Chen, D., Dunstan, C., Lems, W., Stinissen, P., van der Heijde, D., van der Linden, S., Boers, M. (2006). The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis and Rheumatism, 54(6), 1772-1777.
  • Padagas, J., Colloton, M., Shalhoub, V., Kostenuik, P., Morony, S., Munyakazi, L., Guo, M., Gianneschi, D., Shatzen, E., Dunstan, C., et al (2006). The receptor activator of nuclear factor-kappa B ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism. Calcified Tissue International, 78(1), 35-44.
  • Valenta, A., Roschger, P., Fratzl-Zelman, N., Kostenuik, P., Dunstan, C., Fratzl, P., Klaushofer, K. (2005). Combined treatment with PTH (1-34) and OPG increases bone volume and uniformity of mineralization in aged ovariectomized rats. Bone, 37(1), 87-95.
  • Morony, S., Warmington, K., Adamu, S., Asuncion, F., Geng, Z., Grisanti, M., Tan, H., Capparelli, C., Starnes, C., Dunstan, C., et al (2005). The Inhibition of RANKL Causes Greater Suppression of Bone Resorption and Hypercalcemia Compared with Bisphosphonates in Two Models of Humoral Hypercalcemia of Malignancy. Endocrinology, 146(8), 3235-3243.
  • Bekker, P., Holloway, D., Rasmussen, A., Murphy, R., Martin, S., Leese, P., Holmes, G., Dunstan, C., DePaoli, A. (2004). A single dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. Journal of Bone and Mineral Research, 19(7), 1059-1066.
  • Theoleyre, S., Wittrant, Y., Couillaud, S., Vusio, P., Berreur, M., Dunstan, C., Blanchard, F., Rédini, F., Heymann, D. (2004). Cellular activity and signaling induced by osteoprotegerin in osteoclasts: involvement of receptor activator of nuclear factor kB ligand and MAPK. BBA: Biochimica et Biophysica Acta - Molecular Cell Research, 1644 (1), 1-7.
  • Dunstan, C., Zhou, H., Seibel, M. (2004). Fibroblast Growth Factor 23: A Phospatonin Regulating Phosphate Homeostasis? Endocrinology, 145(7), 3084-3086.
  • Wittrant, Y., Theoleyre, S., Couillaud, S., Dunstan, C., Heymann, D., Redini, F. (2004). Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities. Experimental Cell Research: emphasizing molecular approaches to cell biology, 293(2), 292-301.
  • Zwerina, J., Hayer, S., Tohidast-Akrad, M., Bergmeister, H., Redlich, K., Feige, U., Dunstan, C., Kollias, G., Steiner, G., Smolen, J., et al (2004). Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Care and Research, 50(1), 277-290.
  • Kiefer, J., Vessella, R., Quinn, J., Odman, A., Zhang, J., Keller, E., Kostenuik, P., Dunstan, C., Corey, E. (2004). The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. Clinical and Experimental Metastasis, 21(5), 381-387.
  • Body, J., Greipp, P., Coleman, R., Facon, T., Geurs, F., Fermand, J., Harousseau, J., Lipton, A., Mariette, X., Williams, C., Dunstan, C., et al (2003). A Phase 1 Study of AMGN-0007, a Recombinant Osteoprotegerin Construct, in Patients with Multiple Myeloma or Breast Cancer-Related Bone Metastases. Cancer, 97(3), 887-892.
  • Smith, B., Cosenza, M., Mancini, A., Dunstan, C., Gregson, R., Martin, S., Smith, S., Davis, H. (2003). A toxicity profile of osteoprotegerin in the cynomolgus monkey. International Journal of Toxicology, 22, 403-412.
  • Doherty, T., Asotra, K., Fitzpatrick, L., Qiao, J., Wilkin, D., Detrano, R., Dunstan, C., Shah, P., Rajavashisth, T. (2003). Calcification in atherosclerosis: Bone biology and chronic inflammation at the arterial crossroads. Proceedings of the National Academy of Sciences (PNAS), 100(20), 11201-11206.
  • Ashcroft, A., Cruickshank, S., Croucher, P., Perry, M., Rollinson, S., Lippitt, J., Child, J., Dunstan, C., Felsburg, P., Morgan, G., et al (2003). Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Immunity, 19, 849-861.
  • Riggs, B., Khosla, S., Atkinson, E., Dunstan, C., Melton, L. (2003). Evidence that type I osteoporosis results from enhanced responsiveness of bone to estrogen deficiency. Osteoporosis International: with other metabolic bone diseases, 14, 728-733.
  • Fohr, B., Dunstan, C., Seibel, M. (2003). Markers of bone remodeling in metastatic bone disease. Journal of Clinical Endocrinology and Metabolism, 88(11), 5059-5075.
  • Schett, G., Redlich, K., Hayer, S., Zwerina, J., Bolon, B., Dunstan, C., Gortz, B., Schulz, A., Bergmeister, H., Kollias, G., et al (2003). Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Care and Research, 48(7), 2042-2051.
  • Wittrant, Y., Theoleyre, S., Couillaud, S., Dunstan, C., Heymann, D., Redini, F. (2003). Regulation of osteoclast protease expression by RANKL. Biochemical and Biophysical Research Communications, 310, 774-778.
  • Capparelli, C., Morony, S., Warmington, K., Adamu, S., Lacey, D., Dunstan, C., Stouch, B., Martin, S., Kostenuik, P. (2003). Sustained anti-resorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. Journal of Bone and Mineral Research, 18(5), 852-858.
  • Khosla, S., Arrighi, H., Melton, L., Atkinson, E., O'Fallon, W., Dunstan, C., Riggs, B. (2002). Correlates of osteoprotegerin levels in women and men. Osteoporosis International: with other metabolic bone diseases, 13(5), 394-399.
  • Khosla, S., Atkinson, E., Dunstan, C., O'Fallon, W. (2002). Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. Journal of Clinical Endocrinology and Metabolism, 87(4), 1550-1554.
  • Wittrant, Y., Couillaud, S., Theoleyre, S., Dunstan, C., Heymann, D., Redini, F. (2002). Osteoprotegerin differentially regulates protease expression in osteoclast cultures. Biochemical & Biophysical Research Communications. Biochemical and Biophysical Research Communications, 293, 38-44.
  • Romas, E., Sims, N., Hards, D., Lindsay, M., Quinn, J., Ryan, P., Dunstan, C., Martin, T., Gillespie, M. (2002). Osteoprotegerin Reduces Osteoclast Numbers and Prevents Bone Erosion in Collagen-Induced Arthritis. The American Journal of Pathology: cellular and molecular biology of disease, 161(4), 1419-1427.
  • Doherty, T., Uzui, H., Fitzpatrick, L., Tripathi, P., Dunstan, C., Asotra, K., Rajavashisth, T. (2002). Rationale for the role of osteoclast-like cells in arterial calcification. The F A S E B Journal, 16, 577-582.
  • Lipton, A., Ali, S., Leitzel, K., Chinchilli, V., Witters, L., Engle, L., Holloway, D., Bekker, P., Dunstan, C. (2002). Serum osteoprotegerin levels in healthy controls and cancer patients. Clinical Cancer Research, 8, 2306-2310.
  • Redlich, K., Hayer, S., Maier, A., Dunstan, C., Tohidast-Akrad, M., Lang, S., Turk, B., Pietschmann, P., Woloszczuk, W., Haralambous, S., et al (2002). Tumor Necrosis Factor alpha - Mediated Joint Destruction Is Inhibited by Targeting Osteoclasts With Osteoprotegerin. Arthritis Care and Research, 46(3), 785-792.

Conferences

  • Buenzli, P., Pivonka, P., Gardiner, B., Smith, D., Dunstan, C., Mundy, G. (2010). Theoretical analysis of the spatio-temporal structure of bone multicellular units. 9th World Congress on Computational Mechanics and 4th Asian Pacific Congress on Computational Mechanics WCCM-APCOM 2010, Bristol, UK: IOP Publishing.
  • Liu, P., Kalak, R., Lue, Y., Erkkilla, K., Simanainen, U., Zhou, H., Hikim, A., Handelsman, D., Seibel, M., Wang, C., Dunstan, C., et al (2007). XXY Mice have an Osteoporotic Phenotype. 29th Annual Meeting American Society for Bone and Mineral Research (ASBMR), Washington DC, USA: American Society for Bone and Mineral Research.
  • Seibel, M., Blair, J., Perryman, L., Pwint, H., Lelliott, J., De Winter, J., Russell, P., Dunstan, C. (2005). Osteoprotegerin treatment inhibits the growth of lytic prostate cancer lesions in bone. 2nd Joint Meeting of the European Calcified Tissue Society and the International Bone and Mineral Society, New York: Elsevier Science.
  • Meier, C., Meinhardt, U., Greenfield, J., Dunstan, C., Seibel, M. (2005). Serum cathepsin K levels reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget''s disease. 2nd Joint Meeting of the European Calcified Tissue Society and the International Bone and Mineral Society, New York: Elsevier Science.

Magazine / Newspaper Articles

  • Lu, W., McKenzie, D., Dunstan, C., Zreiqat, H., Bilek, M. (2012). Plasma Immersion Ion Implantation Treatment of Poly-ether Ether Ketone for the Immobilization of Biomolecules on Surfaces (ID: 836). International Forum of Biomedical Materials: Nanobiomaterials for Tissue Regeneration.

Reference Works

  • Zhou, H., Chen, D., Dunstan, C., Seibel, M. (2009). Bone Metabolism. In Stefan Offermanns, Walter Rosenthal (Eds.), Bone Metabolism. (Vol. 1, pp. 276-282). USA: Springer.

2013

  • Zheng, Y., Zhou, H., Dunstan, C., Sutherland, R., Seibel, M. (2013). The role of the bone microenvironment in skeletal metastasis. Journal of Bone Oncology, 2(1), 47-57.

2012

  • Pivonka, P., Buenzli, P., Dunstan, C. (2012). A Systems Approach to Understanding Bone Cell Interactions in Health and Disease. In Sivakumar Gowder (Eds.), Cell Interaction, (pp. 169-204). Rijeka, Croatia: InTech Publishers.
  • Smith, D., Gardiner, B., Dunstan, C. (2012). Bone Balance within a Cortical BMU: Local Controls of Bone Resorption and Formation. PLoS One, 7(7), 1-12.
  • Brennan, T., Henneicke, H., Gasparini, S., Blankenstein, K., Heinevetter, U., Cogger, V., Svistounov, D., Zhang, Y., Cooney, G., Buttgereit, F., Dunstan, C., Zhou, H., Seibel, M., et al (2012). Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism. Journal of Clinical Investigation, 122(11).
  • Lu, W., McKenzie, D., Dunstan, C., Zreiqat, H., Bilek, M. (2012). Plasma Immersion Ion Implantation Treatment of Poly-ether Ether Ketone for the Immobilization of Biomolecules on Surfaces (ID: 836). International Forum of Biomedical Materials: Nanobiomaterials for Tissue Regeneration.
  • Roohani-Esfahani, S., Dunstan, C., Davies, B., Pearce, S., Williams, R., Zreiqat, H. (2012). Repairing a critical-sized bone defect with highly porous modified and unmodified baghdadite scaffolds. Acta Biomaterialia, 8(11), 4162-4172.
  • Pivonka, P., Dunstan, C. (2012). Role of mathematical modeling in bone fracture healing. BoneKEy Reports, Report 1 (2012), 221-1-221-10.
  • Lu, Z., Wang, G., Dunstan, C., Zreiqat, H. (2012). Short-Term Exposure to Tumor Necrosis Factor-Alpha Enables Human Osteoblasts to Direct Adipose Tissue-Derived Mesenchymal Stem Cells into Osteogenic Differentiation. Stem Cells and Development, 21(13), 2420-2429.
  • Kam, W., Meikle, S., Dunstan, C., Banati, R. (2012). The 18 kDa Translocator Protein (Peripheral Benzodiazepine Receptor) Expression in the Bone of Normal, Osteoprotegerin or Low Calcium Diet Treated Mice. PLoS One, 7(1), 1-10.

2011

  • Stalgis-Bilinski, K., Boyages, J., Salisbury, E., Dunstan, C., Henderson, S., Talbot, P. (2011). Burning daylight: balancing vitamin D requirements with sensible sun exposure. Medical Journal of Australia, 194(7), 345-348.
  • Wang, Y., Pivonka, P., Buenzli, P., Smith, D., Dunstan, C. (2011). Computational Modeling of Interactions between Multiple Myeloma and the Bone Microenvironment. PLoS One, 6(11), e27494-1-e27494-21.
  • Henneicke, H., Herrmann, M., Kalak, R., Brennan, T., Bertollo, N., Day, R., Huscher, D., Buttgereit, F., Dunstan, C., Seibel, M., Zhou, H. (2011). Corticosterone selectively targets endo-cortical surfaces by an osteoblast-dependent mechanism. Bone, 49(4), 733-742.
  • Fiford, R., Tomitsch, M., Dunstan, C., Plumbe, R. (2011). Exploring how elements of studio teaching can improve student engagement. Synergy, 31(July), 46-52.
  • Ooi, L., Zheng, Y., Stalgis-Bilinski, K., Dunstan, C. (2011). The bone remodeling environment is a factor in breast cancer bone metastasis. Bone, 48(1), 66-70.

2010

  • Goldhahn, J., Little, D., Mitchell, P., Fazzalari, N., Reid, I., Aspenberg, P., Marsh, D., Augat, P., Bavonratanavech, S., Bostrom, M., Dunstan, C., et al (2010). Evidence for anti-osteoporosis therapy in acute fracture situations-Recommendations of a multidisciplinary workshop of the International Society for Fracture Repair. Bone, 46(2), 267-271.
  • Allan, C., Kalak, R., Dunstan, C., McTavish, K., Zhou, H., Handelsman, D., Seibel, M. (2010). Follicle-stimulating hormone increases bone mass in female mice. Proceedings of the National Academy of Sciences (PNAS), Published online before print December 13, 2010, 1-6.
  • Liu, P., Kalak, R., Lue, Y., Jia, Y., Erkkila, K., Zhou, H., Seibel, M., Wang, C., Swerdloff, R., Dunstan, C. (2010). Genetic and Hormonal Control of Bone Volume, Architecture, and Remodeling in XXY Mice. Journal of Bone and Mineral Research, 25(10), 2148-2154.
  • Weber, A., Li, G., Kalak, R., Street, J., Buttgereit, F., Dunstan, C., Seibel, M., Zhou, H. (2010). Osteoblast-targeted disruption of glucocorticoid signalling does not delay intramembranous bone healing. Steroids, 75(3), 282-286.
  • Zreiqat, H., Ramaswamy, Y., Wu, C., Paschalidis, A., Lu, Z., James, B., Birke, O., McDonald, M., Little, D., Dunstan, C. (2010). The incorporation of strontium and zinc into a calcium-silicon ceramic for bone tissue engineering. Biomaterials, 31(12), 3175-3184.
  • Buenzli, P., Pivonka, P., Gardiner, B., Smith, D., Dunstan, C., Mundy, G. (2010). Theoretical analysis of the spatio-temporal structure of bone multicellular units. 9th World Congress on Computational Mechanics and 4th Asian Pacific Congress on Computational Mechanics WCCM-APCOM 2010, Bristol, UK: IOP Publishing.
  • Ooi, L., Zheng, Y., Zhou, H., Trivedi, T., Conigrave, A., Seibel, M., Dunstan, C. (2010). Vitamin D deficiency promotes growth of MCF-7 human breast cancer in a rodent model of osteosclerotic bone metastasis. Bone, 47(4), 795-803.
  • Ooi, L., Zhou, H., Kalak, R., Zheng, Y., Conigrave, A., Seibel, M., Dunstan, C. (2010). Vitamin D deficiency promotes human breast cancer growth in a murine model of bone metastasis. Cancer Research, 70(5), 1835-1844.
  • Zheng, Y., Zhou, H., Ooi, L., Snir, A., Dunstan, C., Seibel, M. (2010). Vitamin D deficiency promotes prostate cancer growth in bone. The Prostate, , 1-10.

2009

  • Mak, W., Shao, X., Dunstan, C., Seibel, M., Zhou, H. (2009). Biphasic Glucocorticoid-Dependent Regulation of Wnt Expression and Its Inhibitors in Mature Osteoblastic Cells. Calcified Tissue International, 85(6), 538-545.
  • Wang, C., Karlis, G., Anderson, G., Dunstan, C., Carbone, A., Berger, G., Ploska, U., Zreiqat, H. (2009). Bone growth is enhanced by novel bioceramic coatings on Ti alloy implants. Journal of Biomedical Materials Research. Part A, 90A(2), 419-428.
  • Zhou, H., Chen, D., Dunstan, C., Seibel, M. (2009). Bone Metabolism. In Stefan Offermanns, Walter Rosenthal (Eds.), Bone Metabolism. (Vol. 1, pp. 276-282). USA: Springer.
  • Dunstan, C., Ooi, L. (2009). CXCL12/CXCR4 Axis in Tissue Targeting and Bone Destruction in Cancer and Multiple Myeloma. Journal of Bone and Mineral Research, 24(7), 1147-1149.
  • Kalak, R., Zhou, H., Street, J., Day, R., Modzelewski, J., Spies, C., Liu, P., Li, G., Dunstan, C., Seibel, M. (2009). Endogenous glucocorticoid signaling in osteoblasts is necessary to maintain normal bone structure in mice. Bone, 45(1), 61-67.
  • Zhou, H., Mak, W., Kalak, R., Street, J., Fong-Yee, C., Zheng, Y., Dunstan, C., Seibel, M. (2009). Glucocorticoid-dependent Wnt signaling by mature osteoblasts is a key regulator of cranial skeletal development in mice. Development (Cambridge), 136(3), 427-436.
  • Dunstan, C. (2009). How can periodontal bone loss be stopped? In Seymour, Robert~Henderson, Brian~Donas, Nikolaos~Curtis, Michael~ (Eds.), Periodontal Medicine and Systems Biology, (pp. 427-237). Chichester, UK: Wiley-Blackwell Publishing.
  • Blair, J., Modzelewski, J., Perryman, L., Russell, P., Seibel, M., Dunstan, C. (2009). Prolonged Antiresorptive Treatment of Lytic Prostate Cancer Xenografts in Mouse Bone Results in Tumor Necrosis. Journal of Cancer Molecules, 4(6), 175-181.
  • Ramaswamy, Y., Wu, C., Dunstan, C., Hewson, B., Eindorf, T., Anderson, G., Zreiqat, H. (2009). Sphene ceramics for orthopedic coating applications: An in vitro and in vivo study. Acta Biomaterialia, 5(8), 3192-3204.
  • Herrmann, M., Henneicke, H., Street, J., Modzelewski, J., Kalak, R., Buttgereit, F., Dunstan, C., Zhou, H., Seibel, M. (2009). The challenge of continuous exogenous glucocorticoid administration in mice. Steroids, 74(2), 245-249.
  • Pivonka, P., Zimak, J., Smith, D., Gardiner, B., Dunstan, C., Sims, N., Martin, T., Mundy, G. (2009). Theoretical investigation of the role of the RANK-RANKL-OPG system in bone remodeling. Journal of Theoretical Biology, 262(2), 306-316.
  • Buttgereit, F., Zhou, H., Kalak, R., Gaber, T., Spies, C., Huscher, D., Straub, R., Modzelewski, J., Dunstan, C., Seibel, M. (2009). Transgenic Disruption of Glucocorticoid Signaling in Mature Osteoblasts and Osteocytes Attenuates K/BxN Mouse Serum-Induced Arthritis In Vivo. Arthritis Care and Research, 60(7), 1998-2007.

2008

  • Zheng, Y., Zhou, H., Fong-Yee, C., Modzelewski, J., Seibel, M., Dunstan, C. (2008). Bone Resorption increases tumour growth in a mouse model of osteosclerotic breast cancer metastasis. Clinical and Experimental Metastasis, 25(5), 559-567.
  • Pivonka, P., Zimak, J., Smith, D., Gardiner, B., Dunstan, C., Sims, N., Martin, T., Mundy, G. (2008). Model structure and control of bone remodeling: A theoretical study. Bone, 43, 249-263.
  • Zhou, H., Mak, W., Zheng, Y., Dunstan, C., Seibel, M. (2008). Osteoblasts directly control lineage commitment of mesenchymal progenitor cells through WNT signaling. Journal of Biological Chemistry, 283(4), 1936-1945.

2007

  • Zheng, Y., Zhou, H., Modzelewski, J., Kalak, R., Blair, J., Seibel, M., Dunstan, C. (2007). Accelerated bone resorption, due to dietary calcium deficiency, promotes breast cancer tumor growth in bone. Cancer Research, 67(19), 9542-9548.
  • Dunstan, C., Blair, J., Zhou, H., Seibel, M. (2007). Bone, Mineral, Connective Tissue Metabolism. In Taylor J; Triggle D (vol ed Michael Williams) (Eds.), Comprehensive Medicinal Chemistry II, (pp. 495-520). Oxford, United Kingdom: Elsevier.
  • Dunstan, C., Felsenberg, D., Seibel, M. (2007). Therapy insight: The risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nature Clinical Practice Oncology, 4(1), 42-45.
  • Liu, P., Kalak, R., Lue, Y., Erkkilla, K., Simanainen, U., Zhou, H., Hikim, A., Handelsman, D., Seibel, M., Wang, C., Dunstan, C., et al (2007). XXY Mice have an Osteoporotic Phenotype. 29th Annual Meeting American Society for Bone and Mineral Research (ASBMR), Washington DC, USA: American Society for Bone and Mineral Research.

2006

  • Zheng, Y., Brennan, K., Blair, J., Modzelewski, J., Seibel, M., Dunstan, C. (2006). Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone, 40(2), 471-478.
  • Blair, J., Zhou, H., Seibel, M., Dunstan, C. (2006). Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nature Clinical Practice Oncology, 3(1), 41-49.
  • Blair, J., Zheng, Y., Dunstan, C. (2006). RANK ligand. The International Journal of Biochemistry and Cell Biology, 39(6), 1077-1081.
  • Meier, C., Meinhardt, U., Greenfield, J., Modzelewski, J., Nguyen, T., Dunstan, C., Seibel, M. (2006). Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget's disease. Clinical Laboratory, 52(1-2), 1-10.
  • Seibel, M., Dunstan, C., Zhou, H., Allan, C., Handelsman, D. (2006). Sex steroids, not FSH, influence bone mass. Cell, 127(6), 1079-1079.
  • Geusens, P., Landewé, R., Garnero, P., Chen, D., Dunstan, C., Lems, W., Stinissen, P., van der Heijde, D., van der Linden, S., Boers, M. (2006). The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis and Rheumatism, 54(6), 1772-1777.
  • Padagas, J., Colloton, M., Shalhoub, V., Kostenuik, P., Morony, S., Munyakazi, L., Guo, M., Gianneschi, D., Shatzen, E., Dunstan, C., et al (2006). The receptor activator of nuclear factor-kappa B ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism. Calcified Tissue International, 78(1), 35-44.

2005

  • Valenta, A., Roschger, P., Fratzl-Zelman, N., Kostenuik, P., Dunstan, C., Fratzl, P., Klaushofer, K. (2005). Combined treatment with PTH (1-34) and OPG increases bone volume and uniformity of mineralization in aged ovariectomized rats. Bone, 37(1), 87-95.
  • Seibel, M., Blair, J., Perryman, L., Pwint, H., Lelliott, J., De Winter, J., Russell, P., Dunstan, C. (2005). Osteoprotegerin treatment inhibits the growth of lytic prostate cancer lesions in bone. 2nd Joint Meeting of the European Calcified Tissue Society and the International Bone and Mineral Society, New York: Elsevier Science.
  • Meier, C., Meinhardt, U., Greenfield, J., Dunstan, C., Seibel, M. (2005). Serum cathepsin K levels reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget''s disease. 2nd Joint Meeting of the European Calcified Tissue Society and the International Bone and Mineral Society, New York: Elsevier Science.
  • Morony, S., Warmington, K., Adamu, S., Asuncion, F., Geng, Z., Grisanti, M., Tan, H., Capparelli, C., Starnes, C., Dunstan, C., et al (2005). The Inhibition of RANKL Causes Greater Suppression of Bone Resorption and Hypercalcemia Compared with Bisphosphonates in Two Models of Humoral Hypercalcemia of Malignancy. Endocrinology, 146(8), 3235-3243.
  • Dunstan, C. (2005). The role of RANK, RANK ligand and osteoprotegerin in the lytic effects and growth of bone metastases. In Claude Jasmin, Lawrence R. Coia, Rodolfo Capanna, Gerard Saillant (Eds.), Textbook of bone metastases, (pp. 51-62). United States: John Wiley & Sons.

2004

  • Bekker, P., Holloway, D., Rasmussen, A., Murphy, R., Martin, S., Leese, P., Holmes, G., Dunstan, C., DePaoli, A. (2004). A single dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. Journal of Bone and Mineral Research, 19(7), 1059-1066.
  • Theoleyre, S., Wittrant, Y., Couillaud, S., Vusio, P., Berreur, M., Dunstan, C., Blanchard, F., Rédini, F., Heymann, D. (2004). Cellular activity and signaling induced by osteoprotegerin in osteoclasts: involvement of receptor activator of nuclear factor kB ligand and MAPK. BBA: Biochimica et Biophysica Acta - Molecular Cell Research, 1644 (1), 1-7.
  • Dunstan, C., Zhou, H., Seibel, M. (2004). Fibroblast Growth Factor 23: A Phospatonin Regulating Phosphate Homeostasis? Endocrinology, 145(7), 3084-3086.
  • Wittrant, Y., Theoleyre, S., Couillaud, S., Dunstan, C., Heymann, D., Redini, F. (2004). Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities. Experimental Cell Research: emphasizing molecular approaches to cell biology, 293(2), 292-301.
  • Zwerina, J., Hayer, S., Tohidast-Akrad, M., Bergmeister, H., Redlich, K., Feige, U., Dunstan, C., Kollias, G., Steiner, G., Smolen, J., et al (2004). Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Care and Research, 50(1), 277-290.
  • Kiefer, J., Vessella, R., Quinn, J., Odman, A., Zhang, J., Keller, E., Kostenuik, P., Dunstan, C., Corey, E. (2004). The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. Clinical and Experimental Metastasis, 21(5), 381-387.

2003

  • Body, J., Greipp, P., Coleman, R., Facon, T., Geurs, F., Fermand, J., Harousseau, J., Lipton, A., Mariette, X., Williams, C., Dunstan, C., et al (2003). A Phase 1 Study of AMGN-0007, a Recombinant Osteoprotegerin Construct, in Patients with Multiple Myeloma or Breast Cancer-Related Bone Metastases. Cancer, 97(3), 887-892.
  • Smith, B., Cosenza, M., Mancini, A., Dunstan, C., Gregson, R., Martin, S., Smith, S., Davis, H. (2003). A toxicity profile of osteoprotegerin in the cynomolgus monkey. International Journal of Toxicology, 22, 403-412.
  • Doherty, T., Asotra, K., Fitzpatrick, L., Qiao, J., Wilkin, D., Detrano, R., Dunstan, C., Shah, P., Rajavashisth, T. (2003). Calcification in atherosclerosis: Bone biology and chronic inflammation at the arterial crossroads. Proceedings of the National Academy of Sciences (PNAS), 100(20), 11201-11206.
  • Ashcroft, A., Cruickshank, S., Croucher, P., Perry, M., Rollinson, S., Lippitt, J., Child, J., Dunstan, C., Felsburg, P., Morgan, G., et al (2003). Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Immunity, 19, 849-861.
  • Riggs, B., Khosla, S., Atkinson, E., Dunstan, C., Melton, L. (2003). Evidence that type I osteoporosis results from enhanced responsiveness of bone to estrogen deficiency. Osteoporosis International: with other metabolic bone diseases, 14, 728-733.
  • Fohr, B., Dunstan, C., Seibel, M. (2003). Markers of bone remodeling in metastatic bone disease. Journal of Clinical Endocrinology and Metabolism, 88(11), 5059-5075.
  • Schett, G., Redlich, K., Hayer, S., Zwerina, J., Bolon, B., Dunstan, C., Gortz, B., Schulz, A., Bergmeister, H., Kollias, G., et al (2003). Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Care and Research, 48(7), 2042-2051.
  • Wittrant, Y., Theoleyre, S., Couillaud, S., Dunstan, C., Heymann, D., Redini, F. (2003). Regulation of osteoclast protease expression by RANKL. Biochemical and Biophysical Research Communications, 310, 774-778.
  • Capparelli, C., Morony, S., Warmington, K., Adamu, S., Lacey, D., Dunstan, C., Stouch, B., Martin, S., Kostenuik, P. (2003). Sustained anti-resorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. Journal of Bone and Mineral Research, 18(5), 852-858.

2002

  • Khosla, S., Arrighi, H., Melton, L., Atkinson, E., O'Fallon, W., Dunstan, C., Riggs, B. (2002). Correlates of osteoprotegerin levels in women and men. Osteoporosis International: with other metabolic bone diseases, 13(5), 394-399.
  • Khosla, S., Atkinson, E., Dunstan, C., O'Fallon, W. (2002). Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. Journal of Clinical Endocrinology and Metabolism, 87(4), 1550-1554.
  • Wittrant, Y., Couillaud, S., Theoleyre, S., Dunstan, C., Heymann, D., Redini, F. (2002). Osteoprotegerin differentially regulates protease expression in osteoclast cultures. Biochemical & Biophysical Research Communications. Biochemical and Biophysical Research Communications, 293, 38-44.
  • Romas, E., Sims, N., Hards, D., Lindsay, M., Quinn, J., Ryan, P., Dunstan, C., Martin, T., Gillespie, M. (2002). Osteoprotegerin Reduces Osteoclast Numbers and Prevents Bone Erosion in Collagen-Induced Arthritis. The American Journal of Pathology: cellular and molecular biology of disease, 161(4), 1419-1427.
  • Doherty, T., Uzui, H., Fitzpatrick, L., Tripathi, P., Dunstan, C., Asotra, K., Rajavashisth, T. (2002). Rationale for the role of osteoclast-like cells in arterial calcification. The F A S E B Journal, 16, 577-582.
  • Lipton, A., Ali, S., Leitzel, K., Chinchilli, V., Witters, L., Engle, L., Holloway, D., Bekker, P., Dunstan, C. (2002). Serum osteoprotegerin levels in healthy controls and cancer patients. Clinical Cancer Research, 8, 2306-2310.
  • Redlich, K., Hayer, S., Maier, A., Dunstan, C., Tohidast-Akrad, M., Lang, S., Turk, B., Pietschmann, P., Woloszczuk, W., Haralambous, S., et al (2002). Tumor Necrosis Factor alpha - Mediated Joint Destruction Is Inhibited by Targeting Osteoclasts With Osteoprotegerin. Arthritis Care and Research, 46(3), 785-792.
Back to Top

Keywords

Breast cancer; Physiology; Osteoporosis; Bone health; Prostate

Back to Top

For support on your academic profile contact Research Support.